| Literature DB >> 31447319 |
Soo Ji Kim1, Girak Kim2, Narae Kim2, Hyuk Chu3, Byung-Chul Park4, Jae Seung Yang5, Seung Hyun Han6, Cheol-Heui Yun7.
Abstract
Human CD141+ dendritic cells (DCs), specialized for cross-presentation, have been extensively studied in the development of DC-based therapy against cancer. A series of attempts was made to generate CD141+ DCs from cord blood CD34+ hematopoietic progenitors to overcome the practical limitation of in vivo rareness. In the present study, we identified a culture system that generates high CD141+ DCs. After culture of CD14+ monocytes in the presence of granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 for 8 days, CD141 was detected on cells that adhered to the bottom of the culture plate. The attached cells exhibited typical features of immature monocyte-derived DCs (moDCs), except for higher CD86 expression, more dendrites and higher granularity compared with those that did not attach. With 3 additional days of culture, increased CD141 expression on the cells was retained along with adhesion ability and partial expression of CLEC9A, a c-type lectin receptor. Furthermore, the cells exhibited effective uptake of dead cells. Interestingly, the attached moDCs differently responded to polyinosinic:polycytidylic acid (poly I:C) stimulation as well as a mixed lymphocyte reaction. Collectively, our findings show that human CD141+ DCs can be sufficiently generated from peripheral blood CD14+ monocytes, potentiating further investigation into generation of higher yields of cross-priming human DCs in vitro.Entities:
Keywords: CD141(+); adhesion; dead cell uptake; granulocyte macrophage colony-stimulating factor/interleukin-4–driven culture system; monocyte-derived dendritic cells
Mesh:
Substances:
Year: 2019 PMID: 31447319 DOI: 10.1016/j.jcyt.2019.07.007
Source DB: PubMed Journal: Cytotherapy ISSN: 1465-3249 Impact factor: 5.414